金沙集团9500(中国)官方网站

CN

CN EN

Latest News

Latest News Media Downloads Video Center

Kexing Biopharm's clinical trial application accepted for human interferon α1b inhalation solution
2022-08-19

2022-08-19

On the evening of August 18, 2022, Kexing Biopharm...
Kexing Biopharm's clinical trial application accepted for another dosage form of human interferon α2b
2022-08-15

2022-08-15

On the evening of August 14, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had recently received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "Human Interferon α2b Spray" was accepted.
Kexing Biopharm's clinical trial application accepted for "Pegylated Human Granulocyte Colony-stimulating Factor Injection"
2022-08-02

2022-08-02

On the evening of August 1, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had just received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "Pegylated Human Granulocyte Colony-stimulating Factor Injection" was accepted.
Kexing Biopharm's conference for reviewing operation and management in first half of 2022and planning key tasks for the second half-year held successfully
2022-08-01

2022-08-01

In the face of the complicated political and economic environment in China and overseas as well as the tough situation in the pharmaceutical industry, Kexing Biopharm proposed the working policy themed as "intensely licensing in new products, firmly promoting R&D and innovation, and proactively creating business in new industries" at the beginning of the year, and continuously followed and implemented the policy in the first half-year.
Phase I clinical trial kick-off meeting of Kexing Biopharm's COVID-19 oral drug SHEN26 Capsule held successfully
2022-07-22

2022-07-22

On July 20, 2022, the phase I clinical trial kick-off meeting of SHEN26 Capsule, a small-molecule oral drug against COVID-19 jointly developed by Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm (688136.SH), and Shenzhen Antiv Pharma Co., Ltd., was successfully held in the Second Affiliated Hospital of Anhui Medical University, indicating the official start of the clinical study for the project.

1 2 3 4 5

Support Hotline

0755-26546500
Online Consultation
QR Code

Scan Code Consultation